|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.25 - 22:03
|
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 (GlobeNewswire EN)
|
|
|
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland the following week....
|
|
|
13.05.25 - 20:30
|
Biotech-Firma Galapagos vollzieht radikale Kehrtwende (Sharedeals)
|
|
|
Radikaler Strategieschwenk bei Galapagos: Der Biotech-Konzern bläst die geplante Ausgliederung ab und verabschiedet CEO Stoffels. Was dieser Kurswechsel für die Zukunft des krisengeplagten Unternehmens und seine Anleger bedeutet. In der Welt der Biotech-Unternehmen sorgt derzeit Galapagos für Aufsehen. Der belgische Konzern, der trotz 25-jähriger Firmengeschichte noch keine zugelassene Therapie vorweisen kann, nimmt eine drastische Strategieänderung […]
The post Biotech-Firma Galapagos vollzieht radikale Kehrtwende first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.04.25 - 07:33
|
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 (GlobeNewswire EN)
|
|
|
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months.Paul Stoffels1, MD, CEO and Chair of the Board of Directors of Galapagos, said “Over the past two years, Thad has worked on the transformation of Galapagos into a focused cell therapy business leveraging our unique decentralized cell therapy platform to deliver fresh, stem-like early memory CAR-T therapy with a vein-to-vein time of seven days. Thad wil...
|
|
|
|
|
|
|
|
|
24.02.25 - 22:03
|
Galapagos to Present at Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March:TD Cowen 45th Annual Healthcare Conference Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: HereBarclays 27th Annual Global Healthcare ConferenceDate: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25 AM ET / 5:00 - 5:25 PM CETLive Webcast Link: HereA live webcast of the presentations can also be accessed on the Investors page of the Company's website at www.glpg.com/investors. Replays of the webcasts will be available following the completion of the event and will be archived for up to 90 days.About GalapagosWe are a biotechnology company with operations in Europe and the U.S. dedicated to...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
